Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PHF19 (PHD finger protein 19) is a polycomb group protein and chromatin modifier characterized by a Tudor domain, two PHD fingers, and an extended homologous (EH) domain[1][2]. As a reader of methylated histone marks, especially H3K36me3 and H3K27me3, PHF19 recruits the Polycomb repressive complex 2 (PRC2), enhancing its methylation activity and facilitating the transition from transcriptionally active to repressed chromatin states. This function is crucial in embryonic stem cell self-renewal and lineage determination, as PHF19 mediates the deposition of repressive H3K27me3 marks by activating PRC2 and recruiting demethylases (e.g., KDM2B)[1][2]. PHF19 is implicated in diseases such as melanoma and rheumatoid arthritis, primarily through its role in gene silencing and cellular differentiation; aberrant PHF19 activity or expression has been associated with tumorigenesis and autoimmune pathogenesis[2]. While no drugs currently target PHF19 directly, its unique histone interaction surfaces have been structurally characterized, potentially enabling future inhibitor or chemical probe development[1].
Not applicable
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on PHD finger protein 19 (PHF19).